One of the most active fields of clinical investigation in immuno-oncology today is augmenting responses to checkpoint [CTLA4 or PD-(L)1] inhibition therapy by re-sensitizing tumors that were initially unresponsive or had stopped responding to treatment. Continue reading
Tag Archives: checkpoint inhibition
Neo-antigen vaccines extend progression-free survival in melanoma
Two companies – Biontech, RNA vaccine and Neon Therapeutics, peptide vaccine – reported very positive results of neo-antigen vaccines in patients with refractory metastatic melanoma. Continue reading
Celgene Collaborates with Jounce Therapeutics on ICOS T-cell Stimulator
Checkpoint inhibitors, alone, are effective in 25% of patients when administered as a single agent. The goal of the collaboration between Celgene and Jounce is to address the other 75% of patients. The lead program is focused on ICOS, the Inducible T cell CO-Stimulator, a protein on the surface of T cells that can spur an immune response against a patient’s cancer. Continue reading